At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RLYB Rallybio Corp.
Trading 05-18 12:00:02 EDT
13.94
-0.36
-2.55%
High14.47Low13.88Vol22.15K
Open14.47D1 Closing14.30Amplitude4.13%
Mkt Cap73.58MTradable Cap35.39MTotal Shares5.28M
T/O313.94KT/O Rate0.87%Tradable Shares2.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ADAR1 Capital Management reports Rallybio common share purchase worth $1.1 million
Reuters  ·  05-16 08:50
ADAR1 Capital Management reports Rallybio common share purchase worth $1.1 million
ADAR1 Capital reports $711,243 Rallybio common shares purchase
Reuters  ·  05-14
ADAR1 Capital reports $711,243 Rallybio common shares purchase
Rallybio Q1 FY26 net loss narrows to $8.28 million; revenue flat at $212,000
Reuters  ·  05-14
Rallybio Q1 FY26 net loss narrows to $8.28 million; revenue flat at $212,000
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares
Reuters  ·  05-07
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Tyson Foods
Reuters  ·  05-04
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Tyson Foods
BRIEF-Rallybio Corp - Candid Terminates Merger Agreement With Rallybio On May 3, 2026 - SEC Filing
Reuters  ·  05-04
BRIEF-Rallybio Corp - Candid Terminates Merger Agreement With Rallybio On May 3, 2026 - SEC Filing
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Norwegian Cruise
Reuters  ·  05-04
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Norwegian Cruise
Rallybio Corp - Entitled to $50 Mln Parent Termination Fee - SEC Filing
THOMSON REUTERS  ·  05-04
Rallybio Corp - Entitled to $50 Mln Parent Termination Fee - SEC Filing
Rallybio says Candid terminates merger agreement, owes $50 million fee
Reuters  ·  05-04
Rallybio says Candid terminates merger agreement, owes $50 million fee
Rallybio Shares Jump 50.5% at $14.14 Premarket After Ucb Offers $2.2 Bln Deal for Candid
THOMSON REUTERS  ·  05-04
Rallybio Shares Jump 50.5% at $14.14 Premarket After Ucb Offers $2.2 Bln Deal for Candid
BUZZ-Rallybio jumps as UCB steps in with $2.2 bln deal for Candid
Reuters  ·  05-04
BUZZ-Rallybio jumps as UCB steps in with $2.2 bln deal for Candid
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger
TIPRANKS  ·  04-01
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger
Rallybio Chief Medical Officer Steven Ryder departs effective immediately
Reuters  ·  04-01
Rallybio Chief Medical Officer Steven Ryder departs effective immediately
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization
TIPRANKS  ·  03-18
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization
Rallybio FY2025 net loss narrowed 84.46% to USD 8.98 million
Reuters  ·  03-17
Rallybio FY2025 net loss narrowed 84.46% to USD 8.98 million
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves
TIPRANKS  ·  03-07
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves
Rallybio in Reverse Merger With Candid Therapeutics
Dow Jones  ·  03-02
Rallybio in Reverse Merger With Candid Therapeutics
BRIEF-Rallybio Corporation And Candid Therapeutics Announce Merger Agreement
Reuters  ·  03-02
BRIEF-Rallybio Corporation And Candid Therapeutics Announce Merger Agreement
Rallybio Corp - Combined Company to Operate as Candid Therapeutics Under Ticker Cdrx
THOMSON REUTERS  ·  03-02
Rallybio Corp - Combined Company to Operate as Candid Therapeutics Under Ticker Cdrx
Rallybio Corp - Candid Secures Oversubscribed and Upsized Private Financing of Over $505 Mln in Gross Proceeds
THOMSON REUTERS  ·  03-02
Rallybio Corp - Candid Secures Oversubscribed and Upsized Private Financing of Over $505 Mln in Gross Proceeds

Introduction

Company Name.
Rallybio Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Issue price:
--